Eli Lilly, GLP-1 regains the lead… upfront payment of 100 billion for acquisition
With Mounjaro and Zepbound, Eli Lilly 2026 year 1quarterly revenue accounted for nearly 2/3 of -1 the GLP8 market lead. Citing patent duration and competitive threats, the company accelerated mergers and acquisitions to diversify its pipeline, and said it executed 100 deals with an upfront payment of 250 billion, with the total potentially rising to as much as
Eli Lilly has risen to the market lead in the GLP-1 category. In its 2026 year 1quarter results, Mounjaro and Zepbound accounted for nearly 2/3 of revenue. The two drugs play a central role in the company’s revenue.
The company acknowledged that the period of patent protection is limited. A pill-form product from Novo Nordisk has been cited as a competitor. The company said it is taking this competitive environment into consideration.
The company is pursuing mergers and acquisitions to diversify its pipeline. It has already completed 8 deals. The combined upfront payments for these deals amount to 100 billion.
If the transaction terms include performance-based additional payments, the total amount could rise to 250billion dollars. The company indicated that more deals are expected to follow. The specific acquisition targets have not yet been disclosed.
Mounjaro and Zepbound are currently the core pillars of revenue. The company explained that the acquisition is intended to strengthen its external pipeline. Details of the transaction are expected to be confirmed in future earnings announcements and additional disclosures.
Sources: The Motley Fool
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.